An annual early-stage biotechnology conference hosted by Merck and Co. (NYSE: MRK) in Boston has resulted in over $100 million in investments over the past six years, from venture capital firms and other sources- and that dollar figure is growing.
The seventh annual Early-Stage Life Sciences Technology Conference, co-sponsored by the Massachusetts Association of Technology Transfer Offices, was held April 14 at Merck Research Laboratories in Boston and included 16 investor pitches by emerging life sciences companies.
The companies included Newton, Mass.-based AcuityBio, which is seeking a $2 million investment to advance its drug delivery platform that is designed to prevent post-surgical cancer recurrance. Boston-based Cellgenix Diagnostics is looking for between $3 million and $5 million in funding to conduct clinical trials for its test to determine which cardiac patients would benefit from drug-eluting stents, and which would have better health outcomes using bare metal stents, which are less costly and have fewer side effects that the newer drug-eluting versions.
To read the full, original article click on this link: Merck biotech forum spurs $100M in investments | Boston Business Journal
Author: Julie M. Donnelly
